Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

In this report, a young Caucasian woman developed a hairy tongue as an unusual side effect during baricitinib therapy for severe alopecia areata, which was managed by daily toothbrush debridement.

This study identified specific profiles and courses of adverse events associated with boron neutron capture therapy for head and neck cancer, suggesting differences based on the beam incidence site.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This study found that in treating mild to moderate acne vulgaris, topical tazarotene 0.1% was more effective than topical adapalene 0.1%, with 100% of patients using tazarotene achieving the desired outcome compared to 75.3% in the adapalene group.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

This study found that both intralesional corticosteroids (TAC) and platelet-rich plasma (PRP) are effective for treating patchy alopecia areata, with TAC providing faster early results but PRP offering better long-term safety and lower relapse rates.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

In this case report, Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, but both developed symptoms of Cushing's Syndrome, prompting the need for careful monitoring due to potential adverse effects when using this treatment.

In this report, an 18-year-old female with trichotillomania was successfully treated using the glutamate modulator n-acetylcysteine.

This study found that oral tofacitinib was significantly more effective than oral minoxidil in reducing disease severity and improving treatment response in patients with alopecia areata over a 12-week period.

In this study, 75% of alopecia areata patients showed improvement after treatment with 35% trichloroacetic acid, leading the researchers to conclude it is a safe and effective option for treating this condition.

This case report details the successful use of oral tofacitinib for six months, which led to significant hair regrowth in an adult male Indian patient with extensive and refractory alopecia areata, highlighting tofacitinib's potential in managing resistant cases within this population.

This article discusses the trichoscopic diagnosis of temporal triangular alopecia, but reports no new clinical results.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This study reviewed various studies and concluded that Janus kinase inhibitors, particularly tofacitinib, seem to promote hair regrowth in about half of patients with alopecia areata, though expected class-specific adverse effects were observed.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study at Gajra Raja Medical College found that topical methotrexate with tretinoin was more effective but not significantly better than betamethasone with tretinoin for treating alopecia areata over six months, with similar safety profiles between the treatments.

In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.

This article explores the therapeutic potential of TECAR therapy for physiotherapy, highlighting its non-invasive nature and ability to provide analgesic, anti-inflammatory, and tissue healing effects across various conditions with minimal side effects when applied correctly.

This study found that both intradermal botulinum toxin A and intradermal minoxidil were equally effective for treating androgenetic alopecia, showing improvement in hair count with advantages like minimal invasiveness and absence of major side effects; minoxidil was also noted to be more cost-effective.

This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study found that an ethanolic extract of Semicarpus anacardium nuts reduced blood glucose levels and improved enzyme activities related to carbohydrate metabolism in normal rats.